In this guide, well break down: The dosing ranges studied so far (112 mg per week) How dosing progression impacts weight loss and tolerability Key differences between Retatrutide dosing and other GLP-1/GIP agonists What the future may hold for clinical and real-world use Table of contents What Is Retatrutide
Landmark clinical trials, such as the STEP programme for semaglutide published in The New England Journal of Medicine, have demonstrated that these medications can lead to average weight loss of 15% or more when combined with lifestyle changes, a level of efficacy previously achievable only through bariatric surgery
BMJ 2025;388:e080679.ArticlePubMedPMC 79
Dysesthesia reported in about 20.9% at the highest dose
While it does activate GLP-1 receptors like semaglutide, it has five times stronger affinity for GIP receptors, creating a metabolic signal your body doesn't get from GLP-1 medications alone
GLP-1 medications do not directly cause pelvic floor dysfunction, but the straining associated with hard, dry stool can trigger or worsen existing coordination problems
